VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 127 filers reported holding VERONA PHARMA PLC in Q2 2024. The put-call ratio across all filers is 1.15 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,247,323 | -46.4% | 501,198 | -40.3% | 0.07% | -44.4% |
| Q1 2024 | $13,511,851 | +35.7% | 839,767 | +67.6% | 0.12% | +14.8% |
| Q4 2023 | $9,959,184 | +4.1% | 500,965 | -14.6% | 0.11% | -3.6% |
| Q3 2023 | $9,563,569 | -9.5% | 586,722 | +17.3% | 0.11% | -10.4% |
| Q2 2023 | $10,570,000 | -69.8% | 500,000 | -71.3% | 0.12% | -73.7% |
| Q1 2023 | $35,024,821 | +436.2% | 1,744,264 | +597.7% | 0.48% | +447.1% |
| Q4 2022 | $6,532,500 | +70.4% | 250,000 | -33.3% | 0.09% | +61.1% |
| Q3 2022 | $3,833,000 | +82.4% | 375,033 | -25.2% | 0.05% | +68.8% |
| Q2 2022 | $2,101,000 | – | 501,458 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners L.P. | 875,000 | $10,387,000 | 10.31% |
| Vivo Capital, LLC | 1,492,951 | $17,723,000 | 3.80% |
| Foresite Capital Management III, LLC | 528,422 | $6,273,000 | 1.76% |
| Novo Holdings A/S | 740,740 | $8,793,000 | 1.23% |
| NEA Management Company, LLC | 1,219,674 | $14,478,000 | 0.60% |
| Orbimed Advisors | 1,250,396 | $14,843,000 | 0.19% |
| Tekla Capital Management LLC | 275,000 | $3,278,000 | 0.13% |
| Perceptive Advisors | 200,000 | $2,384,000 | 0.08% |
| Polar Capital LLP | 95,149 | $1,134,000 | 0.01% |
| MORGAN STANLEY | 15 | $0 | 0.00% |